Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Richardson, Paul [1 ]
Sandhu, Irwindeep [2 ]
Oriol, Albert [3 ,4 ]
Raab, Marc S. [5 ]
White, Darrell [6 ,7 ]
LeBlanc, Richard [8 ]
Perrot, Aurore [9 ]
Ocio, Enrique [10 ]
Raje, Noopur [11 ]
Hansen, Charlotte Toftmann [12 ]
Zhou, Zehua [13 ]
Civardi, Tiziana [14 ]
Ghiddi, Alessandro [14 ]
Katz, Jessica [13 ]
Peluso, Teresa [14 ]
Dimopoulos, Meletios A. [15 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Alberta, Edmonton, AB, Canada
[3] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[4] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[11] Massachusetts Gen Canc Ctr, Boston, MA USA
[12] Odense Univ Hosp, Odense, Denmark
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudry, Switzerland
[15] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-053
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [31] Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma
    Bjorklund, Chad C.
    Amatangelo, Michael
    Chiu, Hsiling
    Kang, Jian
    Civardi, Tiziana
    Katz, Jessica
    Maciag, Paulo
    Hagner, Patrick
    Pourdehnad, Michael
    Bahlis, Nizar J.
    Richardson, Paul G.
    Thakurta, Anjan
    BLOOD, 2021, 138
  • [32] Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
    Weisel, K.
    Palumbo, A.
    Chanan-Khan, A.
    Nooka, A. K.
    Spicka, I.
    Masszi, T.
    Beksac, M.
    Hungria, V.
    Munder, M.
    Mateos, M-V.
    Mark, T. M.
    Spencer, A.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Sonneveld, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [34] Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial
    Weisel, Katja
    Dimopoulos, Meletios
    Oriol, Albert
    Beksac, Meral
    Schjesvold, Frederick
    Liberati, Anna Marina
    Lindsay, Jindriska
    White, Darrell
    San-Miguel, Jesus
    Moreau, Philippe
    Anderson, Larry D., Jr.
    Lorocca, Alessandra
    Robak, Pawel
    Vogel, Prisca
    Jiang, Ruiyun
    Grote, Lara
    Peluso, Teresa
    Richardson, Paul
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 166
  • [35] Results of Study CC-220-MM-001 Dose Expansion of Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients with Relapsed/Relapsed-Refractory Multiple Myeloma (RRMM)
    Knop, S.
    Lonial, S.
    Popat, R.
    Hulin, C.
    Jagannath, S.
    Oriol, A.
    Richardson, P. G.
    Facon, T.
    Weisel, K.
    Larsen, J. T.
    Minnema, M. C.
    Abdallah, A. -O. A.
    Badros, A. Z.
    Stadtmauer, E. A.
    Chen, M.
    Nguyen, T., V
    Amin, A.
    Peluso, T.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 247 - 247
  • [36] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Jakubowiak, A.
    Griffith, K.
    Dytfeld, D.
    Vesole, D.
    Jagannath, S.
    Anderson, T.
    Nordgren, B.
    Detweiler-Short, K.
    Lebovic, D.
    Stockerl-Goldstein, K.
    Jobkar, T.
    Wear, S.
    Al-Zoubi, A.
    Ahmed, A.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Hussein, M.
    Yeganegi, H.
    Vij, R.
    HAEMATOLOGICA, 2012, 97 : 115 - 115
  • [37] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
    Lonial, Sagar
    Popat, Rakesh
    Hulin, Cyrille
    Jagannath, Sundar
    Oriol, Albert
    Richardson, Paul G.
    Facon, Thierry
    Weisel, Katja
    Larsen, Jeremy T.
    Minnema, Monique C.
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Knop, Stefan
    Stadtmauer, Edward A.
    Chen, Min
    Nguyen, Tuong Vi
    Amin, Alpesh
    Kueenburg, Elisabeth
    Peluso, Teresa
    van de Donk, Niels W. C. J.
    BLOOD, 2021, 138
  • [38] PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS)
    Badros, Z.
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Baer, M.
    Egorin, M.
    Grant, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 258
  • [39] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [40] CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma
    Wong, Lilly
    Narla, Rama Krishna
    Leisten, Jim
    Bauer, Daniel
    Groza, Matthew
    Gaffney, Bonny
    Havens, Courtney G.
    Choi, Justin
    Houston, Jack
    Lopez-Girona, Antonia
    Hansen, Joshua
    Cathers, Brian E.
    Carmichael, James
    Pierce, Daniel W.
    BLOOD, 2019, 134
12345